SGMC Health now offers in-house HER2 testing for breast cancer, making it the only provider within a 150-mile radius to offer ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® ...

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...

A Fermanagh woman says a routine breast cancer screening at the Lakeland Forum may have saved her life, after it revealed a tumour she would ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing ...

B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...

But awareness alone isn’t enough. In this milestone year, ACS encourages everyone to do more this October and turn awareness ...

Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over ...